Loading...
XNAS
CUPR
Market cap5mUSD
Oct 08, Last price  
1.90USD
1D
-4.52%
1Q
-61.77%
IPO
-94.70%
Name

Cuprina Holdings (Cayman) Ltd

Chart & performance

D1W1MN
XNAS:CUPR chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
50k
+3.26%
58,50456,599100,77348,32149,894
Net income
-5m
L+199.48%
-519,686-1,094,516-1,119,555-1,560,535-4,673,447
CFO
-9m
L+639.00%
-221,860-1,849,674-1,542,777-1,235,981-9,133,948

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.

Key people

Yong Qi Quek
Chief Executive Officer, Director
Tat Jing Chan
Chief Financial Officer · since 2023
Carl Baptista
Chief Technology Officer, Director
Peng Siew Lee
Non-Executive Director
Non-Executive Director
Independent Director · since 2024
Ivan Ng
Independent Director · since 2024
Natasha Raina
Independent Director · since 2024
IPO date
Apr 10, 2025
Employees
Domiciled in
SG
Incorporated in
KY

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT